Synthesis, Biological Evaluation, and Molecular Modeling of Abiraterone Analogues: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer-Reference-Cited by-同舟云学术

Synthesis, Biological Evaluation, and Molecular Modeling of Abiraterone Analogues: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer

Published:2008-08-01 Issue:16 Volume:51 Page:5009-5018
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pinto-Bazurco Mendieta Mariano A. E.¹,Negri Matthias¹,Jagusch Carsten¹,Müller-Vieira Ursula¹,Lauterbach Thomas¹,Hartmann Rolf W.¹

Affiliation:

1. Pharmaceutical and Medicinal Chemistry, Saarland University, P.O. Box 151150, D-66041 Saarbrücken, Germany, Pharmacelsus CRO, Science Park 2, D-66123 Saarbrücken, Germany, and Schwarz Pharma, Alfred-Nobel-Strasse 10, D-40789 Monheim, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm800355c

Reference50 articles.

1. Cancer Statistics, 2008

2. Advances in the Treatment of Prostate Cancer

3. Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and Biological Evaluation of Methoxypolyethylene-Glycol-Substituted Abiraterone Derivatives as Potential Antiprostate Cancer Agents;Molecular Pharmaceutics;2024-05-30

2. Organophotocatalytic pyridination of N-arylglycines with 4-cyanopyridines by decarboxylative and decyanative radical–radical coupling;Organic & Biomolecular Chemistry;2024

3. Importance of In silico Tools in Anticancer Drug Discovery from Nature;Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach;2023-10-31

4. Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment;Journal of Medicinal Chemistry;2023-05-16

5. Use of PARP inhibitors in prostate cancer: from specific to broader application;Frontiers in Endocrinology;2023-04-21